Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06276595 · ClinicalTrials.gov registry record · NA
Telling Our Daughters Our Story
A NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.
- Completed
- Registry status
- NA
- Development phase
- 183
- Enrollment target
NCT06276595: Completed NA study, sponsored by Johns Hopkins Bloomberg School of Public Health.
NCT06276595 is a NA study that has completed, run by Johns Hopkins Bloomberg School of Public Health. The registered enrollment target is 183 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06276595, a NA study, has completed, sponsored by Johns Hopkins Bloomberg School of Public Health.
- COMPLETED
- Registry status
- NA
- Development phase
- 183 participants
- Enrollment target
Study Summary
The objective of this research study is to evaluate a culturally grounded program among American Indian (AI) female children and the children's female caregivers. This project will evaluate the impact of "Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (henceforth referred to as TODOS) on associated risk and protective factors for early substance use and sexual debut through a randomized controlled trial on the White Mountain Apache (WMA) reservation. The investigators will examine whether the TODOS program effectively reduces risk factors and improves protective factors associated with early substance use and sexual debut, with long term goals of reducing teen pregnancy and teen substance use.
Primary Outcome
Using a questionnaire developed by the study team, investigators will measure change in knowledge from baseline to immediately following the intervention and 6 months and 12 months after program completion via a knowledge assessment completed by the child. This is a 4- question assessment that is on a 5-point Likert scale (score: 0-20) A higher score indicates higher (greater) knowledge.
Interventions
- BEHAVIORAL Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS)
- BEHAVIORAL Control condition - 3 Monthly Group Activities in the Community
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 183 participants |
| Start Date | 2019-03-30 |
| Est. Completion | 2024-07-30 |
| Phase | NA |
What the finished NCT06276595 record still lists
NCT06276595 is an interventional study that assigns participants to a tested intervention. The registered 183 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS) is the first listed.
NCT06276595 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06276595 about?
NCT06276595 is a clinical study titled "Telling Our Daughters Our Story". The objective of this research study is to evaluate a culturally grounded program among American Indian (AI) female children and the children's female caregivers. This project will evaluate the impact of "Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (henceforth referred to as TODOS) on...
What is the current status of trial NCT06276595?
This trial is currently completed. It is a NA study. The enrollment target is 183 participants. The study started on 2019-03-30. Estimated completion is 2024-07-30.
What interventions are being tested in trial NCT06276595?
The interventions under investigation include: Nowhi Isdza bit Nadagoldi: Telling Our Daughters Our Story (TODOS) (BEHAVIORAL), Control condition - 3 Monthly Group Activities in the Community (BEHAVIORAL).
Who is sponsoring clinical trial NCT06276595?
This trial is sponsored by Johns Hopkins Bloomberg School of Public Health, which has 187 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06276595's enrollment target sits among peer trials
183 584th of 2000 higher than 1,417 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03859297 · 183 participants · NA
Mechanisms of Rumination Change in Adolescent Depression
- NCT04270591 · 183 participants · Phase 1
Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer
- NCT06764615 · 183 participants · Phase 2
A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD)
- NCT06872684 · 183 participants · NA
Safety and Efficacy of Endovascular Treatment of Intracranial Aneurysms With Surpass Elite With GUARDian Flow Diverter (GUARD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI